Skip to main content

Table 1 The clinical outcome of HID-HSCT and trials comparing allo-HSCT with chemotherapy or TKI

From: The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology

Author [ref.]

Patients

No

Diagnosis

CIR

OS

LFS

Wang et al. [27], 2013

HID-HSCT, retrospective

756

Leukemia

15% (SR), 26% (HR) at 2 years

 

68% (SR) at 3 years 49% (HR) at 3 years

Huang et al. [15], 2012

HID-HSCT vs CT prospective

58 vs 74

AML-CR1 adults IR or HR

12 vs 57%*

7.5 vs 54.7%* at 4 years

73.1 vs 44.2%* at 4 years

Zhu et al. [35], 2013

HSCT vs CT

58 vs 58

ETO(+) adults AML-CR1

22.1 vs 78.9% (HR)* 14.7 vs 5.3% (LR)

71.6 vs 26.7% (HR)* 75.7 vs 100% (LR)

61.7 vs 19.6% (HR)* 70.3 vs 94.7% (LR)

Qin et al. [36], 2015

HSCT vs CT

57 vs 29

In(16) adults AML-CR1

7.1 vs. 87.7% (poor MR)*; 0 vs. 26.9% (good MR);

93.3 vs. 40.0%, (poor MR)*; 72.9 vs. 77.1% (good MR)

86.7 vs. 12.3% (poor MR)* 72.9 vs. 73.1% (good MR)

Yan et al. [82], 2014

HID-HSCT vs CT

79 vs 59

SR-ALL-CR1 adults

29.9 vs 66.3%* at 5 years

70.4 vs 28%* at 5 years

54.4 vs 23.9%* at 5 years

Sun et al. [83], 2014

HID-HSCT vs CT

79 vs 104

HR-ALL-CR1 adults

18.7 vs 60.5%* at 3 years

72.5 vs 26.6%*; at 3 years

63.9 vs 21.1%* at 3 years

Wang et al. [84], 2012

HID-HSCT, T-ALL

72

T-ALL

18.8% (CR1) 37.5% (non-CR1)

 

54.8% (CR1) 12.5% (non-CR1)

Xu et al. [46], 2016

HSCT

52

Pediatric T-ALL(HR)

32.7% at 3 years

55.5% at 3 years

54.1% at 3 years

Jiang et al. [85], 2011

HSCT vs IM

87 vs 45

CML-AP adults

 

81.2 vs 100% (LR) at 6 years 81.3 vs 61.3% (IR)* at 6 years 100 vs 17.7% (HR)* at 5years

80.7 vs 80.9% (LR) at 6 years, 61.9 vs 47.1% (IR)* at 6 years 66.7 vs 9.3% (HR)* at 5 years

Xu et al. [52], 2016

HSCT vs TKI2

60 vs 33

CML-AP adults

 

86.4 vs. 42.9%* at 5 years

76.1 vs. 14.3%* at 5 years

  1. HID haploidentical donor, MRD matched-related donor, HSCT hematopoietic stem cell transplantation CT, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndrome, LR low risk, IR intermediate risk, HR high risk, T_ALL T cell ALL, MR molecular response, ph Philadephia chromosome[t(9;22)], CML chronic myeloid leukemia, CP chronic phase, AP accelerated phase, BC blast crisis, IM imatinib, TKI2 second-generation TKI, SAA severe aplastic anemia. * The difference was significance between two groups (P<0,05)